Regulatory approval

Published by the Health Canada.

Health Canada approved olaparib as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability.

This is written in the approval document as:

LYNPARZA (olaparib) is indicated as an add-on maintenance treatment to bevacizumab of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability. BRCA mutation status (germline or somatic) and/or genomic instability must be confirmed before LYNPARZA treatment is initiated.

Citation

AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HC (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
HC (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
HC (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
HC (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Bevacizumab, Olaparib
HC (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
HC (1) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
HC (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
HC (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Bevacizumab, Olaparib
HC (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
HC (1) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
HC (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib
HC (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Bevacizumab, Olaparib